Portopulmonary hypertension -: Survival and prognostic factors

被引:167
|
作者
Le Pavec, Jerome [1 ]
Souza, Rogerio [1 ]
Herve, Philippe [1 ]
Lebrec, Didier [2 ,3 ]
Savale, Laurent [1 ]
Tcherakian, Colas [1 ]
Jais, Xavier [1 ]
Yaici, Azzedine [1 ]
Humbert, Marc [1 ]
Simonneau, Gerald [1 ]
Sitbon, Olivier [1 ]
机构
[1] Univ Paris 11, Hop Antoine Beclere, AP HP, Serv Pneumol & Reanimat,UPRES 2705, Clamart, France
[2] Hop Beaujon, INSERM, U773, Ctr Rech Biomed Bichat Beaujon,CRB3,AP HP, Clichy, France
[3] Hop Beaujon, AP HP, Serv Hepatol, Clichy, France
关键词
pulmonary hypertension; portal hypertension; portopulmonary hypertension; cirrhosis; survival;
D O I
10.1164/rccm.200804-613OC
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Rationale: Portopulmonary hypertension (PoPH) can be defined as elevation of pulmonary arterial pressure and pulmonary vascular resistance in the setting of portal hypertension. Survival results in PoPH are contrasting, and prognostic factors need to be identified. Objectives: To analyze long-term survival in a large cohort of patients with PoPH with the aim of determining the independent variables affecting survival. Methods: We retrospectively analyzed charts of all patients referred to the French Referral Center for pulmonary arterial hypertension with the diagnosis of PoPH between 1984 and 2004. Measurements and Main Results: The study population comprised 154 patients; 57% male. Mean age at diagnosis was 49 +/- 11 years, 60%of patients were in New York Heart Association functional class III-IV, and mean 6-minute walk distance was 326 +/- 116 m. Hemodynamic measurements showed a mean pulmonary arterial pressure of 53 +/- 13 mm Hg, cardiac index of 2.9 0.9 L/min/m(2), and pulmonary vascular resistance of 752 +/- 377 dyn/s/cm(5). Portal hypertension was related to cirrhosis in 136 patients, with a severity assessed as follows: Child-Pugh class A 51%, Child-Pugh class B 38%, Child-Pugh class C 11%. Overall survival rates at 1, 3, and 5 yr were 88, 75, and 68%, respectively. Multivariate regression analysis individualized the presence and severity of cirrhosis and cardiac index as major independent prognostic factors. Conclusions: Prognosis in PoPH is mainly related to the presence and severity of cirrhosis and to cardiac function. The place of pulmonary arterial hypertension-specific therapies remains to be determined in the setting of PoPH.
引用
收藏
页码:637 / 643
页数:7
相关论文
共 50 条
  • [31] Portopulmonary hypertension
    Nayak R.P.
    Li D.
    Matuschak G.M.
    Current Gastroenterology Reports, 2009, 11 (1) : 56 - 63
  • [32] Hemodynamic Profile and Survival of Patients with Portopulmonary Hypertension in Chinese Population
    Li, Y.
    Sun, Y.
    Wang, L.
    Yuan, P.
    Gong, S.
    Liu, J.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2021, 203 (09)
  • [33] PREDICTORS OF SURVIVAL IN PORTOPULMONARY HYPERTENSION: A 20-YEAR EXPERIENCE
    Aggarwal, Manik
    Bhardwaj, Abhishek
    Wallace, William D.
    Li, Manshi
    Singh, Achintya D.
    Dweik, Raed
    Heresi, Gustavo
    Tonelli, Adriano
    GASTROENTEROLOGY, 2021, 160 (06) : S859 - S859
  • [34] Prognostic factors for survival in scleroderma associated pulmonary arterial hypertension
    Johnson, Sindhu R.
    Swinton, John R.
    Granton, John T.
    JOURNAL OF RHEUMATOLOGY, 2008, 35 (08) : 1584 - 1590
  • [35] Survival in portopulmonary hypertension: Outcomes of the United Kingdom National Pulmonary Arterial Hypertension Registry
    Sithamparanathan, Sasiharan
    Nair, Arun
    Thirugnanasothy, Logan
    Coghlan, J. Gerry
    Condliffe, Robin
    Dimopoulos, Konstantinos
    Elliot, Charlie A.
    Fisher, Andrew J.
    Gaine, Sean
    Gibbs, J. Simon R.
    Gatzoulis, Michael A.
    Handler, Clive E.
    Howard, Luke S.
    Johnson, Martin
    Kiely, David G.
    Lordan, James L.
    Peacock, Andrew J.
    Pepke-Zaba, Joanna
    Schreiber, Benjamin E.
    Sheares, Karen K. K.
    Wort, Stephen J.
    Corris, Paul A.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2017, 36 (07): : 770 - 779
  • [36] Portopulmonary hypertension: An update
    Porres-Aguilar, Mateo
    Mukherjee, Debabrata
    RESPIROLOGY, 2015, 20 (02) : 235 - 242
  • [37] Survival in portopulmonary hypertension: Mayo Clinic experience categorized by treatment subgroups
    Swanson, K. L.
    Wiesner, R. H.
    Nyberg, S. L.
    Rosen, C. B.
    Krowka, M. J.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2008, 8 (11) : 2445 - 2453
  • [38] Portopulmonary Hypertension: Prevalence and Survival in Patients Undergoing Liver Transplantation.
    Boin, I.
    Shimozono, E.
    Caruy, C.
    Cardoso, A.
    Servian, D.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2014, 14 : 796 - 796
  • [39] Macitentan for portopulmonary hypertension
    Van Epps, Heather
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2019, 4 (02): : 98 - 98
  • [40] Portopulmonary hypertension: An update
    Safdar, Zeenat
    Bartolome, Sonja
    Sussman, Norman
    LIVER TRANSPLANTATION, 2012, 18 (08) : 881 - 891